GLUE earnings: real EPS beat/miss history, analyst consensus Buy, P/E -12.79. Updated 2026-07-23.
Monte Rosa Therapeutics (GLUE) Research Hub
Monte Rosa Therapeutics (GLUE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 14.07 USD (-1.33%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -12.79, market cap 1.52B. This hub links to the full technical, earnings and options research available for GLUE.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 14.07 USD (-1.33%) |
| 52-week range | 13.37 USD – 25.22 USD |
| Trend regime | Range |
| 14-day RSI | 35.2 (Bearish) |
| Trailing P/E | -12.79 |
| Market cap | 1.52B |
| Dividend yield | 0.00% |
Available research for GLUE
Covered Call on GLUE: how it works, illustrative setup around the real 14.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GLUE: how it works, illustrative setup around the real 14.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GLUE: how it works, illustrative setup around the real 14.07 USD price, max profit/loss, breakeven and when to use it. Educational.
GLUE technical analysis: range, last 14.07 USD, RSI 35.2, 52w range 13.37 USD–25.22 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is GLUE in?
Monte Rosa Therapeutics (GLUE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GLUE in an uptrend or downtrend?
As of 2026-09-11, GLUE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GLUE's trailing P/E ratio?
GLUE's trailing P/E is -12.79, with a market cap of 1.52B. See the earnings research page for full valuation detail.